Cynapsus Therapeutics Announces 2016 Analyst and Investor Day
(Thomson Reuters ONE) -
TORONTO, July 06, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc.
(NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical
company developing and preparing to commercialize a fast-acting, easy-to-use,
sublingual thin film for the on-demand management of debilitating OFF episodes
associated with Parkinson's disease (PD), today announced that it will host an
analyst and investor day on Tuesday, July 19, 2016.
The meeting will include presentations from Cynapsus executives and world-
renowned clinical experts in PD. The event will start at 7:00 a.m. and will
conclude at approximately 9:30 a.m. EDT.
A webcast of the event will be available in the investor section of Cynapsus'
website at www.cynapsus.ca. A replay of the webcast will be available on the
website for 30 days after the conclusion of the event.
Speakers to include:
* C. Warren Olanow, M.D., Mt. Sinai School of Medicine, New York
* Fabrizio Stocchi, M.D., PhD, IRCCS San Raffaele Rome, Italy
* Anthony Giovinazzo, President & CEO of Cynapsus
* Albert Agro, Ph.D., Chief Medical Officer of Cynapsus
About Cynapsus
Cynapsus is a specialty CNS pharmaceutical company developing and preparing to
commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand
management of debilitating OFF episodes associated with PD. Cynapsus
successfully completed a Phase 2 clinical trial for its product candidate, APL-
130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.
Apomorphine is the only molecule approved for acute, intermittent treatment of
OFF episodes for advanced PD patients, but is currently only approved as a
subcutaneous injection in the United States. APL-130277 is a "turning ON"
medication designed to rapidly, safely and reliably convert a PD patient from
the OFF to the ON state while avoiding many of the issues associated with
subcutaneous delivery of apomorphine. It is designed to convert all types of OFF
episodes, including morning OFF episodes, often considered the most difficult to
treat. Cynapsus' Phase 3 clinical program for APL-130277 plans to rely on the
abbreviated Section 505(b)(2) regulatory pathway in the United States, and the
company intends to submit a new drug application (NDA) near the end of 2016 or
in early 2017. For additional company information, please visit our
website www.cynapsus.ca. For more information about the Phase 3 studies please
visit the websitehttp://cth300and301trials.cynapsus.ca/
Forward-Looking Statements
This announcement contains "forward-looking statements" within the meaning of
applicable securities laws, including, without limitation, the Company's
expectation for filing an NDA near the end of 2016 or in early 2017; and
expectations regarding the Company's clinical and regulatory activities,
including without limitation, the anticipated timing and completion of clinical
studies. These forward-looking statements include information about possible or
assumed future results of the Company's business, financial condition, results
of operations, liquidity, plans and objectives. In some cases, you can identify
forward-looking statements by terminology such as "believe," "may," "estimate,"
"continue," "anticipate," "intend," "should," "plan," "expect," "predict,"
"potential," or the negative of these terms or other similar expressions. These
forward-looking statements are based on the Company's current expectations and
beliefs and inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ from those anticipated in such
forward-looking statements as a result of risks and uncertainties, and include,
but are not limited to, those factors identified under the caption "Risk
Factors" in the Company's quarterly report on Form 10-Q for the quarter ended
March 31, 2016 filed with the United States Securities and Exchange Commission
(the "SEC") on May 11, 2016, and its other filings and reports in the United
States with the SEC available on the SEC's web site at www.sec.gov, and in
Canada with the various Canadian securities regulators, which are available
online at www.sedar.com. Furthermore, unless otherwise stated, the forward-
looking statements contained in this press release are made as of the date of
this press release, and the Company has no intention and undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events, changes or otherwise, except as
required by law.
Neither the NASDAQ nor the TSX has approved or disapproved of the contents of
this press release.
Contact Information
Company Contact:
Kristen Galfetti
Vice President, Investor Relations
(416) 703-2449 x246
kgalfetti(at)cynapsus.ca
Event Contact:
The Trout Group
Jennifer Porcelli
Senior Vice President
(646) 378-2962
jporcelli(at)troutgroup.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cynapsus Therapeutics Inc. via GlobeNewswire
[HUG#2026099]
Unternehmensinformation / Kurzprofil:
Datum: 06.07.2016 - 12:00 Uhr
Sprache: Deutsch
News-ID 481841
Anzahl Zeichen: 6029
contact information:
Town:
Toronto, Ontario
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cynapsus Therapeutics Announces 2016 Analyst and Investor Day"
steht unter der journalistisch-redaktionellen Verantwortung von
Cynapsus Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
